An analysis on validity of distribution of biomarkers, exploration of correlation between biomarker outliers and adverse events under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 2 study)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Atrial fibrillation; Paroxysmal atrial fibrillation
- Focus Biomarker; Pharmacodynamics
- Acronyms R-mark (CVI ARO 2) study
- 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 Status changed from not yet recruiting to recruiting.
- 01 Jul 2016 New trial record